Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07775924 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

Study acronym: ELIPSI
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 9 → 18 locations Eligibility criteria expanded, about 12 words · Secondary endpoints: details revised at 3 of 6 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 3 of 6 entries
  2. Trial sites expanded: 6 → 9 locationsv5
  3. Study sites: 4 to 6v4
  4. Recruitment opened Study sites: 2 to 4v3 Show 1 more changeShow less
    • Study sites: 2 to 4
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2v2 Show 1 more changeShow less
    • Study sites: 0 to 2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
This study will evaluate the safety and efficacy of GIA632 in participants with moderate to severe cutaneous lichen planus (cLP).
Trial Details
NCT Number NCT07775924
Lead Sponsor Novartis Pharmaceuticals
Conditions Cutaneous Lichen Planus
Enrollment 259 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov